Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of FDA018-ADC versus investigator's choice chemotherapy in taxane-failed advanced triple-negative breast cancer
CTR20242630Phase 3Active
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of FDA018-ADC in triple-negative breast cancer (TNBC), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started Aug 2024; status: active.
02
Drugs
FDA018-ADC
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20242630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242630.